Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma

Cellular Oncology

Volumn 29, Issue 6, 2007, Pages 453-466

  Zaffaroni, Nadia ^a   Costa, Aurora ^a   Pennati, Marzia ^a   De Marco, Cinzia ^a   Affini, Emanuela ^a   Madeo, Maria ^a   Erdas, Roberta ^a   Cabras, Antonello ^a   Kusamura, Shigeki ^a   Baratti, Dario ^a   Deraco, Marcello ^a   Daidone, Maria Grazia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apoptosis; Caspase 9; IAPs; Peritoneal mesothelioma; siRNA; Survivin

Indexed keywords

CASPASE 9; CISPLATIN; DOXORUBICIN; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; INHIBITOR OF APOPTOSIS PROTEIN X; MESSENGER RNA; SURVIVIN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CATALYSIS; CELL GROWTH; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FUNCTIONAL PROTEOMICS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT NEOPLASTIC DISEASE; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RNA INTERFERENCE;

ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MESOTHELIOMA; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PERITONEAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 36248989049     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. D.C. Altieri, Survivin and apoptosis control, Adv. Cancer Res. 88 (2003), 31-52.
2. D.C. Altieri, Survivin, versatile modulation of cell division and apoptosis in cancer, Oncogene 22 (2003), 8581-8589.
3. D.C. Altieri, Validating survivin as a cancer therapeutic target, Nat. Rev. Cancer 3 (2003), 46-54.
4. D.C. Altieri, The case of survivin as a regulator of microtubule dynamics and cell-death decisions, Curr. Opin. Cell Biol. 18 (2006), 609-615.
5. A. Carvalho, M. Carmena, C. Sambade et al., Survivin is required for stable checkpoint activation in taxol-treated HeLa cells, J. Cell Sci. 116 (2003), 2987-2998.
6. E.M. Creagh, B.M. Murphy, P.J. Duriez, C.S. Duckett and S.J. Martin, Smac/Diablo antagonizes ubiquitin ligase activity of inhibitor of apoptosis proteins, J. Biol. Chem. 279 (2004), 26906-26914.
7. M. Deraco, N. Santoro, O. Carraro et al., Peritoneal carcinomatosis: Feature of dissemination, A review, Tumori 85 (1999), 1-5.
8. M. Deraco, M. De Simone, C.R. Rossi et al., An Italian Multicentric phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with peritoneal mesothelioma, J. Exp. Clin. Cancer Res. 22 (2003), 41-45.
9. Q.L. Deveraux and J.C. Reed, IAP family proteins-suppressors of apoptosis, Genes Dev. 13 (1999), 239-252.
10. C. Du, M. Fang, Y. Li, L. Li and X.Wang, Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition, Cell 102 (2000), 33-42.
11. M. Falleni, C. Pellegrini, A. Marchetti et al., Quantitative evaluation of the apoptosis regulating genes, Lung Cancer 48 (2005), 211-216.
12. D.A. Fennell and R.M. Rudd, Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development, Lancet Oncol. 5 (2004), 354-362.
13. U. Fischer and K. Schulze-Osthoff, New approaches and therapeutics targeting apoptosis in disease, Pharmacol. Rev. 57 (2005), 187-215.
14. G.J. Gordon, K. Appasani, J.P. Parcells et al., Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma, Carcinogenesis 23 (2002), 1017-1024.
15. G.J. Gordon, M. Mani, L. Mukhopadhyay et al., Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma, J. Pathol. 211 (2007), 447-454.
16. D. Grossman, J.M. McNiff, F. Li and D.C. Altieri, Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma, J. Invest. Dermatol. 113 (1999), 1076-1081.
17. D. Grossman, P.J. Kim, J.S. Schechner and D.C. Altieri, Inhibition of melanoma tumor growth in vivo by survivin targeting, Proc. Natl. Acad. Sci. USA 98 (2001), 635-640.
18. S. Hopkins-Donaldson, R. Cathomas, A.P. Simoes-Wust et al., Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment, Int. J. Cancer 106 (2003), 160-166.
19. S. Kusamura, R. Younan, D. Baratti et al., Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique, Cancer 106 (2006), 1144-1153.
20. F. Li, J. Yang, N. Ramnath, M.M. Javle and D. Tan, Nuclear or cytoplasmic expression of survivin: what is the significance?, Int. J. Cancer 114 (2005), 509-512.
21. M. Markman and D. Kelsen, Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma, J. Cancer Res. Clin. Oncol. 118 (1992), 547-550.
22. Y. Morizane, R. Honda, K. Fukami and H. Yasuda, X-linked inhibitor of apoptosis functions as ubiquitin ligase toward mature caspase-9 and cytosolic Smac/DIABLO, J. Biochem. - Tokyo 137 (2005), 125-132.
23. D. Nonaka, S. Kusamura, D. Baratti et al., Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution, Cancer 104 (2005), 2181-2188.
24. D.S. O'Connor, D. Grossman, J. Plescia et al., Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin, Proc. Natl. Acad. Sci. USA 97 (2000), 13103-13107.
25. S.L. O'Kane, R.J. Pound, A. Campbell et al., Expression of bcl-2 family members in malignant pleural mesothelioma, Acta Oncol. 45 (2006), 449-453.
26. M.K. Ozvaran, X.X. Cao, S.D. Miller et al., Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma, Mol. Cancer Ther. 3 (2004), 545-550.
27. F. Paduano, R. Villa, M. Pennati et al., Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells, Mol. Cancer Ther. 5 (2006), 179-186.
28. M. Pennati, G. Colella, M. Folini et al., Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis, J. Clin. Invest. 109 (2002), 285-286.
29. M. Pennati, M. Binda, G. Colella et al., Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression, J. Invest. Dermatol. 120 (2003), 648-654.
30. M. Pennati, M. Binda, G. Colella et al., Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells, Oncogene 23 (2004), 386-394.
31. B. Price, Analysis of current trends in United States mesothelioma incidence, Am. J. Epidemiol. 145 (1997), 211-218.
32. J.C. Reed, The survivin saga goes in vivo, J. Clin. Invest. 108 (2001), 965-969.
33. G.S. Salvesen and V.M. Dixit, Caspase activation: the induced-proximity model, Proc. Natl. Acad. Sci. USA 96 (1999), 10964-10967.
34. G.S. Salvesen and C.S. Duckett, IAP proteins: blocking the road to death's door, Nat. Rev. Mol. Cell Biol. 3 (2002), 401-410.
35. Z. Song, X. Yao and M. Wu, Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis, J. Biol. Chem. 278 (2003), 23130-23140.
36. P.H. Sugarbaker, T.D. Yan, O.A. Stuart and D. Yoo, Comprehensive management of diffuse malignant peritoneal mesothelioma, Eur. J. Surg. Oncol. 32 (2006), 686-691.
37. B. Vischioni, P. van der Valk, S.W. Span et al., Expression and localization of inhibitor of apoptosis proteins in normal human tissues, Hum. Pathol. 37 (2006), 78-86.
38. L. Weissmann, R. Osteen, J. Corson et al., Combined modality therapy for intraperitoneal mesothelioma, Proc. Am. Soc. Clin. Oncol. 7 (1988), 274.
39. M. Wu, S. Yuan, A.H. Szporn et al., Immunocytochemical detection of XIAP in body cavity effusions and washes, Modern Pathol. 18 (2005), 1618-1622.
40. C. Xia, Z. Xu, X. Yuan et al., Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides, Mol. Cancer Ther. 1 (2002), 687-694.
41. N.J. Yoo, H.S. Kim, S.Y. Kim et al., Immunohistochemical analysis of Smac/DIABLO expression in human carcinomas and sarcomas, APMIS 111 (2003), 382-388.
42. N. Zaffaroni, M. Pennati and M.G. Daidone, Survivin as a target for new anticancer interventions, J. Cell Mol. Med. 9 (2005), 360-372.
43. th AACR Annual Meeting (April 1-5, 2006 -Washington, USA).
44. D.E. Zhu, N. Hoti, Z. Song et al., Suppression of tumor growth using a recombinant adenoviral vector carrying the dominant-negative mutant gene Survivin-D53A in a nude mice model, Cancer Gene Ther. 13 (2006), 762-770.